122 related articles for article (PubMed ID: 31788317)
1. Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Perez RP; Chen E; Thaddeus Beck J; Shirai K; Neil Hayes D; Shen T; Baldwin JR; Bryant KB; He S; Chin S
Pharmacol Res Perspect; 2019 Dec; 7(6):e00519. PubMed ID: 31788317
[TBL] [Abstract][Full Text] [Related]
2. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
[TBL] [Abstract][Full Text] [Related]
5. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma.
Yanamoto S; Umeda M; Kioi M; Kirita T; Yamashita T; Hiratsuka H; Yokoo S; Tanzawa H; Uzawa N; Shibahara T; Ota Y; Kurita H; Okura M; Hamakawa H; Kusukawa J; Tohnai I
Cancer Chemother Pharmacol; 2018 Mar; 81(3):549-554. PubMed ID: 29383483
[TBL] [Abstract][Full Text] [Related]
6. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
[TBL] [Abstract][Full Text] [Related]
8. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma.
Surmeli ZG; Ozveren A; Arslan C; Degirmenci M; Karaca B; Uslu R
Indian J Cancer; 2019; 56(1):4-8. PubMed ID: 30950435
[TBL] [Abstract][Full Text] [Related]
9. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
Mutlu H; Salim DK; Gündüz Ş; Eryılmaz MK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2017; 13(3):510-513. PubMed ID: 28862218
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Thomas M; Sadjadian P; Kollmeier J; Lowe J; Mattson P; Trout JR; Gargano M; Patchen ML; Walsh R; Beliveau M; Marier JF; Bose N; Gorden K; Schneller F
Invest New Drugs; 2017 Jun; 35(3):345-358. PubMed ID: 28303530
[TBL] [Abstract][Full Text] [Related]
12. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Joerger M; von Pawel J; Kraff S; Fischer JR; Eberhardt W; Gauler TC; Mueller L; Reinmuth N; Reck M; Kimmich M; Mayer F; Kopp HG; Behringer DM; Ko YD; Hilger RA; Roessler M; Kloft C; Henrich A; Moritz B; Miller MC; Salamone SJ; Jaehde U
Ann Oncol; 2016 Oct; 27(10):1895-902. PubMed ID: 27502710
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F; Alix-Panabières C; Lafont T; Allal BC; Garrel R; Digue L; Guigay J; Cupissol D; Delord JP; Lallemant B; Alfonsi M; Aubry K; Mazel M; Becher F; Perriard F; Chatelut E; Thomas F
Br J Clin Pharmacol; 2019 Jun; 85(6):1357-1366. PubMed ID: 30811063
[TBL] [Abstract][Full Text] [Related]
14. Towards risk-stratified induction regimens.
Killock D
Nat Rev Clin Oncol; 2019 Apr; 16(4):209. PubMed ID: 30647429
[No Abstract] [Full Text] [Related]
15. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Felici A; Loos WJ; Verweij J; Cirillo I; de Bruijn P; Nooter K; Mathijssen RH; de Jonge MJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):673-80. PubMed ID: 16544143
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
[TBL] [Abstract][Full Text] [Related]
20. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
